Predominant, Winning & Stupid – The Health Care Blog
[ad_1] By MATTHEW HOLT In recent days and weeks, there have been three stories that have really brought home to me the inanity of how […]
Long term care spending around the world – Healthcare Economist
[ad_1] A great paper by Gruber et al. 2023 looks at the evolution of long-term care for ten countries: Canada, […]
Are AI Clinical Protocols A Dobb-ist Trojan Horse? – The Health Care Blog
[ad_1] By MIKE MAGEE For most loyalist Americans at the turn of the 19th century, Justice John Marshall Harlan’s decision in Jacobson v. Massachusetts (1905). […]
We Freeze People, Don’t We? – The Health Care Blog
[ad_1] By KIM BELLARD Perhaps you’ve heard about the controversial Alabama Supreme Court ruling about in-vitro fertilization (IVF), in which the court declared that frozen […]
Putting the ‘value’ in value-based payments – The Health Care Blog
[ad_1] By JOSH SEIDMAN Like Matthew Holt, I have also been ranting about the fact that “We’re spending way too much money on stuff that […]
55% of US Rural Hospitals Are No Longer Offer Birthing Services – Healthcare Economist
[ad_1] That is according to an article in JAMA based on a report from the Center for Healthcare Quality and Payment Reform. The report states: […]
So what can we do about health care costs? – The Health Care Blog
[ad_1] By MATTHEW HOLT Last week Jeff Goldsmith wrote a great article in part explaining why health care costs in the US went up so […]
How will Medicaid pay for cell and gene therapies? – Healthcare Economist
[ad_1] One approach CMS has is the Cell and Gene Therapy (CGT) Access Model. Under the CGT Access Model, CMS (at the federal level) will […]
Why Does the United States Pay, by Far, the Highest Prices in the World for Prescription Drugs? – Healthcare Economist
[ad_1] That is the topic of a U.S. Senate hearing last week. One person testifying was an economist, USC Professor […]
Utilization management for biosimilars – Healthcare Economist
[ad_1] When we think of utilization management (e.g., prior authorizations, step edits), we often think payers only use these for higher cost branded products including […]